MAPKAPK2 and cancer: Specifically, the silencing of the MAP kinase MK2 in SKBR3 cells led to a reduction in the abundance of phosphorylated ZFP36/TTP, indicating this pathway’s involvement in ERBB2-amplified cancer cells (Fig. 6C).